Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.12 USD
+0.03 (1.44%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Cellectar Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 39 | 29 | 24 | 15 | 14 |
Income After Depreciation & Amortization | -39 | -29 | -24 | -15 | -14 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -38 | -29 | -24 | -15 | -14 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -38 | -29 | -24 | -15 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -38 | -29 | -24 | -15 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -39 | -29 | -24 | -15 | -14 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -39 | -29 | -24 | -15 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.22 | 7.06 | 5.55 | 1.98 | 0.77 |
Diluted EPS Before Non-Recurring Items | -3.15 | -4.05 | -4.30 | -7.60 | -18.40 |
Diluted Net EPS (GAAP) | -3.11 | -4.05 | -4.30 | -7.60 | -18.40 |
Fiscal Year end for Cellectar Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 12.00 | 12.55 | 9.41 | 8.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -12.00 | -12.55 | -9.41 | -8.30 |
Non-Operating Income | NA | -9.58 | 5.04 | -4.32 | 0.07 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -21.58 | -7.51 | -13.73 | -8.22 |
Income Taxes | NA | 0.00 | -0.06 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -21.58 | -7.45 | -13.73 | -8.22 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -21.58 | -7.45 | -13.73 | -8.22 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.35 | 18.62 | 11.31 | 11.26 |
Diluted EPS Before Non-Recurring Items | NA | -0.40 | -0.66 | -0.82 | -0.73 |
Diluted Net EPS (GAAP) | NA | -0.74 | -0.41 | -1.21 | -0.73 |